These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 12683130)

  • 21. Data and market exclusivity for pharmaceuticals in the European Community.
    Kingham RF; Castle GH
    Food Drug Law J; 2000; 55(2):209-23. PubMed ID: 12269365
    [No Abstract]   [Full Text] [Related]  

  • 22. Can China bring its own pipeline to the market?
    Louët S
    Nat Biotechnol; 2004 Dec; 22(12):1497-9. PubMed ID: 15583646
    [No Abstract]   [Full Text] [Related]  

  • 23. Pediatric medicine. Europe follows U.S. in testing drugs for children.
    Bosch X
    Science; 2005 Sep; 309(5742):1799. PubMed ID: 16166486
    [No Abstract]   [Full Text] [Related]  

  • 24. The shape of European business in 2003.
    Wagner M
    Med Device Technol; 2002 Dec; 13(10):8-10. PubMed ID: 12575520
    [No Abstract]   [Full Text] [Related]  

  • 25. FDA and EMEA pool scientific advice.
    Katsnelson A
    Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642
    [No Abstract]   [Full Text] [Related]  

  • 26. [Standardization and quality in the clinical laboratory : towards an European system of clinical laboratory sciences].
    Fuentes-Arderiu X
    Ann Biol Clin (Paris); 2001; 59(2):225-30. PubMed ID: 11282529
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug marketing exclusivity under United States and European Union law.
    Junod V
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract]   [Full Text] [Related]  

  • 28. Regulatory watch: Where do new medicines originate from in the EU?
    Lincker H; Ziogas C; Carr M; Porta N; Eichler HG
    Nat Rev Drug Discov; 2014 Feb; 13(2):92-3. PubMed ID: 24481298
    [No Abstract]   [Full Text] [Related]  

  • 29. Where is industry getting it wrong? A review of quality concerns raised at Day 120 by the Committee For Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products.
    Borg JJ; Robert JL; Wade G; Aislaitner G; Pirozynski M; Abadie E; Salmonson T; Vella Bonanno P
    J Pharm Pharm Sci; 2009; 12(2):181-98. PubMed ID: 19732496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug evaluation and approval process in the European Union.
    San Miguel MT; Vargas E
    Arthritis Rheum; 2006 Feb; 55(1):12-4. PubMed ID: 16463405
    [No Abstract]   [Full Text] [Related]  

  • 31. [Does collaboration inside the European Union improve Finnish drug safety?].
    Palva E
    Duodecim; 2000; 116(24):2810-1. PubMed ID: 12077885
    [No Abstract]   [Full Text] [Related]  

  • 32. European perspectives on pediatric formulations.
    Breitkreutz J
    Clin Ther; 2008 Nov; 30(11):2146-54. PubMed ID: 19108802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drugs in 2001: a number of ruses unveiled.
    Prescrire Int; 2002 Apr; 11(58):58-60. PubMed ID: 11987319
    [No Abstract]   [Full Text] [Related]  

  • 34. [Children on the drug development map. The Danish Society of Clinical Pharmacology].
    Thirstrup S; Heisterberg J;
    Ugeskr Laeger; 2008 Mar; 170(12):1039. PubMed ID: 18397657
    [No Abstract]   [Full Text] [Related]  

  • 35. International Conference on Harmonisation; guidance on Q8(R1) Pharmaceutical Development; addition of annex; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jun; 74(109):27325-6. PubMed ID: 19588572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [EURO-Medicines: a European program for bringing into agreement public health policies on drugs].
    Calamo-Specchia F; Bucci R; Folino-Gallo P
    Ann Ig; 1998; 10(5-6):405-12. PubMed ID: 10052204
    [No Abstract]   [Full Text] [Related]  

  • 37. Moving toward a paradigm shift in the regulatory requirements for pediatric medicines.
    Chin WW; Joos A
    Eur J Pediatr; 2016 Dec; 175(12):1881-1891. PubMed ID: 27646479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Experiences of the drug approval processes in the European Union].
    Pasanen M; Toivonen M
    Duodecim; 2000; 116(24):2817-22. PubMed ID: 12077887
    [No Abstract]   [Full Text] [Related]  

  • 39. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Drugs in Europe].
    Bouzy C; Abadie E
    Rev Prat; 2002 Mar; 52(5):510-4. PubMed ID: 11949504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.